# Losartan to Improve Hip Microfracture

> **NCT04212650** · PHASE1,PHASE2 · TERMINATED · sponsor: **Steadman Philippon Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Hip Osteoarthritis
- Hip Impingement Syndrome
- Cartilage Damage
- Fibrosis

## Interventions

- **DRUG:** Losartan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04212650
- **Lead sponsor:** Steadman Philippon Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-07
- **Primary completion:** 2020-12-04
- **Final completion:** 2020-12-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** redesigned trial using another placebo controlled drug
- **Last updated:** 2023-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212650, "Losartan to Improve Hip Microfracture". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04212650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*